NasdaqGS:BCEL

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Atreca, Inc., a biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. More Details


Snowflake Analysis

Flawless balance sheet and overvalued.

Share Price & News

How has Atreca's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: BCEL has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-0.8%

BCEL

-1.2%

US Biotechs

0.4%

US Market


1 Year Return

44.4%

BCEL

32.5%

US Biotechs

17.8%

US Market

Return vs Industry: BCEL exceeded the US Biotechs industry which returned 32.5% over the past year.

Return vs Market: BCEL exceeded the US Market which returned 17.8% over the past year.


Shareholder returns

BCELIndustryMarket
7 Day-0.8%-1.2%0.4%
30 Day12.0%2.3%6.1%
90 Day13.3%-2.6%8.9%
1 Year44.4%44.4%34.7%32.5%20.5%17.8%
3 Yearn/a20.0%14.0%42.3%32.9%
5 Yearn/a11.5%3.4%84.2%63.4%

Price Volatility Vs. Market

How volatile is Atreca's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Atreca undervalued compared to its fair value and its price relative to the market?

2.65x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate BCEL's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate BCEL's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: BCEL is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: BCEL is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BCEL's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: BCEL is good value based on its PB Ratio (2.7x) compared to the US Biotechs industry average (3.4x).


Next Steps

Future Growth

How is Atreca forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

-13.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BCEL is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: BCEL is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: BCEL is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if BCEL's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if BCEL's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if BCEL's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Atreca performed over the past 5 years?

-43.6%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: BCEL is currently unprofitable.

Growing Profit Margin: BCEL is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if BCEL's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare BCEL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BCEL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7.1%).


Return on Equity

High ROE: BCEL has a negative Return on Equity (-49.56%), as it is currently unprofitable.


Next Steps

Financial Health

How is Atreca's financial position?


Financial Position Analysis

Short Term Liabilities: BCEL's short term assets ($148.6M) exceed its short term liabilities ($7.4M).

Long Term Liabilities: BCEL's short term assets ($148.6M) exceed its long term liabilities ($3.1M).


Debt to Equity History and Analysis

Debt Level: BCEL is debt free.

Reducing Debt: BCEL has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BCEL has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: BCEL has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of 37.9% each year.


Next Steps

Dividend

What is Atreca current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate BCEL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BCEL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BCEL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BCEL's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BCEL's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.5yrs

Average management tenure


CEO

John Orwin (55 yo)

2.5yrs

Tenure

US$725,014

Compensation

Mr. John A. Orwin has been President, Chief Executive Officer and Director at Atreca, Inc. since April 19, 2018 Mr. Orwin has been a Director of Relypsa, Inc since June 2013 and Seagen Inc. (formerly known ...


CEO Compensation Analysis

Compensation vs Market: John's total compensation ($USD725.01K) is below average for companies of similar size in the US market ($USD1.93M).

Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
John Orwin
President2.5yrsUS$725.01k0.017%
$ 87.0k
Tito Serafini
Co-Founder10.75yrsUS$637.49k1.12%
$ 5.9m
Norman Greenberg
Chief Scientific Officer5.42yrsUS$1.11mno data
Herbert Cross
Chief Financial Officer1.67yrsno data0%
$ 0
Yann Tan
Chief Technologistno datano datano data
Courtney Phillips
General Counsel & Corporate Secretary1.25yrsno datano data
Daniel Emerling
Senior Vice President of Researchno datano datano data
Lisa Decker
Chief Business Officer1.25yrsno datano data
Jonathan Benjamin
Senior Vice President of Clinical Research0.25yrno datano data

1.5yrs

Average Tenure

53yo

Average Age

Experienced Management: BCEL's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
John Orwin
President2.5yrsUS$725.01k0.017%
$ 87.0k
Tito Serafini
Co-Founder10.75yrsUS$637.49k1.12%
$ 5.9m
Brian Atwood
Independent Chairman of the Board6.83yrsUS$64.13k0%
$ 0
Lawrence Steinman
Chairman of External Scientific Advisory Board & Technical Advisor1.17yrsUS$150.00k0.72%
$ 3.7m
Franklin Berger
Independent Director6yrsUS$41.28k0.27%
$ 1.4m
Kristine Ball
Director0.42yrno datano data
William Robinson
Director9.75yrsUS$272.65k1.09%
$ 5.7m
David Lacey
Independent Director4.42yrsUS$38.87k0%
$ 0
Douglas Crawford
Board Observerno datano datano data
Andrew Farnum
Board Observerno datano datano data
Lindsey Rolfe
Independent Director1.17yrsUS$383.72kno data

4.4yrs

Average Tenure

57yo

Average Age

Experienced Board: BCEL's board of directors are considered experienced (4.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 28.9%.


Top Shareholders

Company Information

Atreca, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Atreca, Inc.
  • Ticker: BCEL
  • Exchange: NasdaqGS
  • Founded: 2010
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$522.787m
  • Shares outstanding: 36.03m
  • Website: https://www.atreca.com

Number of Employees


Location

  • Atreca, Inc.
  • 450 East Jamie Court
  • South San Francisco
  • California
  • 94080
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BCELNasdaqGS (Nasdaq Global Select)YesClass A Common StockUSUSDJun 2019
0C1MUN (Boerse Muenchen)YesClass A Common StockDEEURJun 2019
0C1DB (Deutsche Boerse AG)YesClass A Common StockDEEURJun 2019

Biography

Atreca, Inc., a biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody in c ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/26 05:36
End of Day Share Price2020/10/23 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.